Cerespir Incorporated Appoints Sophie Egholm as Chief Operating Officer
April 30, 2015 09:00 ET
|
CereSpir Inc.
NEW YORK, April 30, 2015 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class modulator of the brain's innate immune system, as a potential treatment for...
CereSpir Incorporated Appoints Eric Karran, Ph.D., as Chairman of Its Scientific Advisory Board
January 07, 2015 09:00 ET
|
CereSpir Inc.
NEW YORK, Jan. 7, 2015 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class modulator of the brain's innate immune system, as a potential treatment for...
CereSpir Incorporated Appoints Adrian N. Hobden, Ph.D., as Chairman of Its Board of Directors
September 30, 2014 09:00 ET
|
CereSpir Inc.
NEW YORK, Sept. 30, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease (AD),...
CereSpir Incorporated Announces the Inauguration of Its Clinical Advisory Board
February 21, 2014 09:00 ET
|
CereSpir Inc.
NEW YORK, Feb. 21, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing the first-in-class microglial modulator CHF 5074 as a potential treatment for Alzheimer's disease (AD),...
CereSpir Incorporated Announces Chris Griffett Will Serve as Vice President, Regulatory Affairs
January 10, 2014 09:00 ET
|
CereSpir Inc.
NEW YORK, Jan. 10, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator as a potential treatment for Alzheimer's disease, today...
CereSpir Incorporated Appoints Richard Margolin, MD, as Vice President, Clinical Development
November 26, 2013 09:00 ET
|
CereSpir Inc.
NEW YORK, Nov. 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease,...
CereSpir Incorporated Secures Exclusive Worldwide Development and Commercialization Rights for CHF 5074 From Chiesi Farmaceutici S.p.A.
November 08, 2013 09:00 ET
|
CereSpir Inc.
NEW YORK and PARMA, Italy, Nov. 8, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today announced CereSpir has acquired the worldwide development and...
CereSpir Incorporated is Pleased With Positive Interim Phase 2 Results for CHF 5074 in Patients With Mild Cognitive Impairment, Presented by Chiesi at the AAIC 2013 Meeting in Boston
July 26, 2013 10:38 ET
|
CereSpir Inc.
Patients with Mild Cognitive Impairment treated with CHF 5074 for up to 90 weeks demonstrated highly statistically significant improvements in verbal memory and executive...
CereSpir Incorporated Announces Letter of Intent With Chiesi Farmaceutici SpA, to License Worldwide Development and Commercialization Rights for CHF 5074 to CereSpir
July 26, 2013 10:33 ET
|
CereSpir Inc.
CHF 5074 is a novel, first-in-class small molecule microglia modulator created by Chiesi
Final results of a 14-week, double-blind, placebo-controlled Phase 2 study in 96 MCI patients and...